Clinical trials: Androgens
Prostate Cancer
Open-Label, Randomised Parallel-Group Study
An Open-Label, Multi-Centre, Randomised Parallel-Group Study, Investigating Efficacy and Safety of Different Degarelix Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring Androgen Ablation Therapy.
- Trial name
- NCT00728533
- Testing
- Degarelix
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasm
A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC).
- Trial name
- NCT01337518
- Testing
- EZN-4176
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Prostate Cancer
S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer
RATIONALE: Hormones can stimulate the production of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00004124
- Testing
- bicalutamide, goserelin, mitoxantrone hydrochloride
- Where
- 234 sites in United States
- Volunteers
- 983 people
- Sponsor
- SWOG Cancer Research Network
Metastatic Castration-resistant Prostate Cancer
The COSMYC Trial (COmbined Suppression of MYC)
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that…
- Trial name
- NCT06922318
- Testing
- ZEN-3694, Testosterone cypionate, Enzalutamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Androgen Levels
Effects of Probiotic Supplementation on Androgen Levels
The goal of this clinical trial is to evaluate the feasibility, safety, and preliminary effects of a probiotic supplement, Bacillus coagulans strain BRCAS-C3, on androgen levels in adult men and women.
- Trial name
- NCT07911813
- Testing
- Bacillus coagulans BRCAS-C3
- Where
- Taiwan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hypogonadism
Oral Testosterone for the Treatment of Hypogonadism
Low testosterone is a condition that occurs when the body is unable to produce sufficient quantities of testosterone. The medical name for low testosterone is hypogonadism. Hypogonadism can be caused by many factors.
- Trial name
- NCT01717768
- Testing
- TSX-002
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- TesoRx Pharma, LLC
Prostate Cancer
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical…
- Trial name
- NCT00658697
- Testing
- Docetaxel, Bevacizumab, ADT
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Polycystic Ovary Syndrome
Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
The mechanism for increased androgen production in women with polycystic ovary syndrome (PCOS) is not well understood. Excess androgen production by the ovary is stimulated by increased pituitary luteinizing hormone (LH)…
- Trial name
- NCT00747617
- Testing
- recombinant human chorionic gonadotropin
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Prostate Carcinoma
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood.
- Trial name
- NCT04484818
- Testing
- Darolutamide, Goserelin Acetate, Leuprolide Acetate
- Where
- 115 sites in United States
- Volunteers
- 27 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer of Prostate
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with…
- Trial name
- SAVE (NCT03899077)
- Testing
- Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant
- Where
- 9 sites in Belgium
- Volunteers
- 202 people
- Sponsor
- Cancer Research Antwerp
Advanced Prostate Cancer
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph…
- Trial name
- NCT02420977
- Testing
- Pelvic DCFPyL PET-MRI fusion or PET/MRI
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms
AR-inhibitor Bicalutamide in Treating Patients With TNBC
Growing studies demonstrated that Androgen Receptor (AR) has an oncogenic role for the patients with AR-positive Triple Negative Breast Cancer (TNBC).
- Trial name
- Arbre (NCT02353988)
- Testing
- Bicalutamide, Physician's Choice
- Volunteers
- 60 people
- Sponsor
- Jinling Hospital, China
High Risk Prostate Carcinoma
Towards Optimal Treatment for High Risk Prostate Cancer
The goal of this clinical trial is to combine several optimized treatments of high risk prostate cancer. The main question to answer is: is it safe to combine these optimized treatments.
- Trial name
- HYPOPRIME (NCT06204341)
- Testing
- HYPOPRIME treatment
- Where
- Netherlands
- Volunteers
- 207 people
- Sponsor
- Haaglanden Medical Centre
Prostatic Neoplasms
MLN2704 in Subjects With Metastatic Androgen-Independent Prostate Cancer
The purpose of the study is to determine the highest dose of MLN2704 that can be given multiple times safely to patients with prostate cancer, and to identify any side effects associated with taking the drug.
- Trial name
- NCT00070837
- Testing
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Where
- 4 sites in United States
- Volunteers
- 46 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Metastatic Hormone-Sensitive Prostate Cance
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise…
- Trial name
- GUARD-QUANTUM (NCT07717099)
- Testing
- Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT)
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Prostate Cancer, Bone Metastases
Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases
Newly diagnosed metastatic prostate cancer subjects with bone metastases will be accrued to this stratified randomized 2-arm Phase II trial. Subjects will be randomized 1:2 to ADT or ADT with Radium-223 dichloride respectively.
- Conditions
- Prostate Cancer, Bone Metastases, Prostate Neoplasms
- Trial name
- NCT02582749
- Testing
- LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
- Where
- 12 sites in United States
- Volunteers
- 16 people
- Sponsor
- Ajjai Alva, MD
Prostate Cancer
The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer
Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time of castration resistant prostate…
- Trial name
- ADTPSMA2 (NCT03876912)
- Testing
- GnRH antagonist
- Where
- Finland
- Volunteers
- 35 people
- Sponsor
- Turku University Hospital
Infertility
Basal Androgens and LH Needing for Ovarian Stimulation for in Vitro Fertilization
Basing the investigators study on the evidence that basal serum androgens decrease with age, the investigators hypothesize that women with serum androgens below a certain level could be the population obtaining a benefit of…
- Trial name
- NCT01563809
- Testing
- FSH+LH
- Where
- Spain
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
Prostatic Neoplasms
Vaccine and Antibody Treatment of Prostate Cancer
This study will evaluate the side effects of a fixed dose of vaccine and GM-CSF with increasing doses of anti-CTLA-4 antibody in patients with advanced prostate cancer.
- Trial name
- NCT00113984
- Testing
- PROSTVAC-V/TRICOM, PROSTVAC-F/TRICOM, MDX-010
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the rate of radiological disease progression with the new 2nd generation positron emission tomography (PET) radiopharmaceutical, 18F-DCFPyL, in patients with metastatic castration (mCRPC) and non-metastatic…
- Trial name
- NCT03800784
- Testing
- 18F-DCFPyL Injection
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.